A Multicenter Pilot Study Evaluating the Safety and Efficacy of Imatinib as Post-Transplant Therapy for High- Risk Philadelphia Chromosome-Positive Leukemias
- Determine the safety of adjuvant imatinib mesylate after allogeneic hematopoietic stem
cell transplantation (AHSCT) in patients with high-risk Philadelphia
- Determine the bcr/abl transcript load during the first 90 days after AHSCT in patients
treated with this drug from the time of engraftment.
- Determine the 1-year survival of patients treated with this drug.
OUTLINE: This is an open-label, pilot, multicenter study.
Beginning within 14-30 days after allogeneic stem cell transplantation, patients receive
oral imatinib mesylate once daily until 1 year after transplantation. Treatment continues in
the absence of unacceptable toxicity or disease progression.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Safety at 90 days following transplant
Paul Carpenter, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|
|City of Hope Comprehensive Cancer Center||Duarte, California 91010|